Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study

Pandit, Anuja; Bhalani, Nirav; Bhushan, Bharat; Koradia, Parshottam; Gargiya, Shweta; Bhomia, Vinay; Kansagra, Kevinkumar

doi:10.1016/j.ijid.2021.03.015

Public

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study

Published in International Journal of Infectious Diseases • Mar 11, 2021

Authors:

Anuja Pandit

Nirav Bhalani

Bharat Bhushan

Abstract

OBJECTIVE: To evaluate the efficacy and safety of pegylated interferon alfa-2b (PEG IFN-α2b) along with the standard of care (SOC) in subjects with moderate COVID-19. METHODS: In this phase 2, randomized, open-label study, adult subjects aged ≥18 years with RT-PCR confirmed COVID-19 with moderate sy...

Subject

Medicine

Randomized controlled trial

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!